Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CureVac NV CVAC

Healthcare Biotechnology
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Recent & Breaking News (NDAQ:CVAC)

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Accesswire May 8, 2023

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

Accesswire April 25, 2023

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

Accesswire April 18, 2023

CureVac Announces Voting Results of Extraordinary General Meeting

Accesswire March 28, 2023

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

Accesswire February 10, 2023

CureVac Announces Proposed Public Offering of Common Shares

Accesswire February 7, 2023

CureVac Welcomes Myriam Mendila as New Chief Development Officer

Accesswire February 1, 2023

CureVac Named as One of the World's Most Dynamic Innovators by LexisNexis(R)

Accesswire January 31, 2023

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

Accesswire January 30, 2023

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

Accesswire January 9, 2023

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

Accesswire January 6, 2023

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

Accesswire December 14, 2022

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

Accesswire November 16, 2022

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Accesswire November 11, 2022

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

Accesswire November 10, 2022

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Accesswire August 18, 2022

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Accesswire August 18, 2022

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Accesswire July 5, 2022

CureVac Announces Voting Results of General Meeting

Accesswire June 22, 2022

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

Accesswire June 8, 2022